Expanding Manufacturing Capacity ProBio recently launched GMP-grade Adeno-Associated Virus (AAV) manufacturing services at its advanced 128,000-square-foot facility, indicating a significant boost in its production capabilities, presenting opportunities for clients seeking scalable gene therapy manufacturing solutions.

Innovative Therapeutic Development With ongoing projects like Hair Loss Antibody Therapy and a focus on advanced biologics such as mRNA vaccines and viral vectors, ProBio demonstrates a commitment to cutting-edge therapies—ideal for partners seeking expertise in novel drug development and manufacturing.

Financial Strength and Market Presence With revenues estimated between $100 million and $250 million and over $220 million in funding, ProBio has the financial backing necessary to invest in innovative projects and expand service offerings, making it a reliable partner for scaling complex therapeutics.

Active Industry Engagement Participation in prominent events such as the Cell Therapy Annual Meeting and several industry presentations reflects ProBio’s active engagement in the biotech community, creating networking opportunities and positioning the company as a forward-thinking leader in the CDMO sector.